HC Wainwright assumed coverage on shares of Opexa Therapeutics (NASDAQ:ACER) in a report published on Wednesday, December 20th, Marketbeat Ratings reports. The firm issued a buy rating on the biopharmaceutical company’s stock.
Separately, ValuEngine cut shares of Opexa Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st.
Shares of Opexa Therapeutics (ACER) traded down $1.22 during trading on Wednesday, hitting $18.28. The stock had a trading volume of 72,800 shares, compared to its average volume of 42,797. The firm has a market capitalization of $136.15, a P/E ratio of -4.54 and a beta of 2.23. Opexa Therapeutics has a 12 month low of $5.70 and a 12 month high of $22.63.
Opexa Therapeutics (NASDAQ:ACER) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter. analysts predict that Opexa Therapeutics will post -1.48 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://ledgergazette.com/2018/01/13/opexa-therapeutics-acer-receives-new-coverage-from-analysts-at-hc-wainwright.html.
About Opexa Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.